secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sunshine Biopharma Inc. (SBFM)
CIK:        0001402328
Form:       8-K
Filed at:   2024-06-07T23:59:59+00:00
Accession:  0001683168-24-004053
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Nasdaq notifies Sunshine Biopharma of delisting due to warrant dilution
-----------------------------------------------------------------------

- Nasdaq staff determined to delist SBFM under Rule 5101 citing public interest concerns over Series A warrant cashless exercise provision.
- Provision allowed warrant holders to receive 2x shares without adjusting for 1-for-100 reverse split on April 17, 2024, causing massive shareholder dilution.
- Company must present views to Nasdaq Hearings Panel by June 14, 2024; no immediate effect on listing pending panel decision.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1402328/000168316824004053/0001683168-24-004053-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1402328/000168316824004053/sunshine_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-24-004053

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer